|
1) Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusion for patients with haematological malignancies; who need them？ Br J Haematol. 2011; 154: 425-40
|
|
|
|
2) Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendation for the transfusion of plasma and platelets. Blood Transfus. 2009; 7: 132-50
|
|
|
|
|
|
3) Gmür J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet. 1991; 338: 1223-6
|
|
|
|
|
|
4) Lawrence JB, Yomotovian RA, Dillman C, et al. Reliability of automated platelet counts: comparison with manual method and utility for prediction of clinical bleeding. Am J Hematol. 1995; 48: 244-50
|
|
|
|
|
|
5) The trial to reduce alloimmunization to platelet study group. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent allo-immunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337: 1861-9
|
|
|
|
|
|
6) Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009; 49: 440-52
|
|
|
|
|
|
7) 藤村吉博. ADAMTS13-TMAの診断と治療の重要指標-. 日本血栓止血学会誌. 2006; 17: 144-64
|
|
|
|
|
8) Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of chest physicians evidence based clinical practice guidelines(8th edition). Chest. 2008; 133: 340S-80S
|
|
|
|
|
|
9) British Committee for Standards in Haematology Blood Transfusion Task Force. Guideline: Guidelines for the use of platelet transfusions. Br J Med. 2003; 122: 10-3
|
|
|
|
|
|
10) 血液製剤の使用にあたって. 第4版. 東京: じほう; 2009
|
|
|
|
|
|
11) Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelets transfusions and prevention of hemorrhage. N Engl J Med. 2010; 362: 600-13
|
|
|
|
|
|
12) Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med. 1980; 31: 509-40
|
|
|
|
|
|
13) Hamajima N, Sasaki R, Aoki K, et al. A notable change in mortality of aplastic anemia observed during the 1970s in Japan. Blood. 1988; 72: 995-9
|
|
|
|
|
|
14) Saito H. Normal hemostatic mechanisms. In: Ratonoff OD, Forbes CD, editors. Disorders of Hemostasis, 3rd. Philladelphia: WB Saunders; 1996. p.23-52
|
|
|
|
|
|
15) Slichter JS. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004; 18: 153-67
|
|
|
|
|
|
16) Nachman RL, Raffi S. Platelets, petechiae and preservation of vascular wall. N Engl J Med. 2008; 359: 1261-70
|
|
|
|
|
|
17) Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood. 1985; 56: 1105-9
|
|
|
|
|
|
18) Segal HC, Briggs C, Kunka S, et al. Accuracy of platelet counting haematology analyzers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Med. 2005; 128: 520-5
|
|
|
|
|
|
19) 上田恭典. 血液疾患における血小板輸血療法: 適応及びトリガーポイント. 臨床血液. 2010; 51: 1523-30
|
|
|
|
|
|
20) Slichter SJ, Harker LA. Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin Haematol. 1978; 7: 523-39
|
|
|
|
|
|
21) Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflam-mation induces hemorrhage in thrombocytopenia. Blood. 2008; 111: 4958-64
|
|
|
|
|
|
22) Friedmann AM, Sengul H, Lehmann H, et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients: A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002; 16: 34-45
|
|
|
|
|
|
23) Diedrich B, Remberger M, Shanwell AS, et al. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10×109 per L versus 30×109 per L in allogenic hematopoietic progenitor cell transplant patients. Transfusion. 2005; 45: 1064-72
|
|
|
|
|
|
24) 血液事業の現状 平成22年度統計表. 日本赤十字社: http://www.jrc.or.jp/blood/shiryo/index.html
|
|
|
|
|
|
25) 血液製剤添付文書集. 日本赤十字社 血液事業本部医薬情報課, 編. 2011
|
|
|
|
|
|
26) Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard-and low-dose strategies for transfudion of platelets (SToP) to patients with thrombo-cytopenia. Blood. 2009; 113: 1564-73
|
|
|
|
|